Drug Candidate Buzz: Recent chatter on X about Pasithea Therapeutics (KTTA) has centered on promising updates for its lead drug candidate, PAS-004. Posts highlight strong safety data and positive pharmacokinetic results from Phase 1 trials, sparking excitement among traders. A $1 million grant from the ALS Association has also fueled discussions about the drug’s potential reach.
Stock Volatility: KTTA’s stock price has seen dramatic swings, with some on X noting a surge of over 600% before a pullback. Conversations point to the micro-cap’s tiny float as a driver of sharp momentum, with traders keenly watching for volume spikes. Public offerings, including a recent $60 million deal, are also stirring debate about dilution risks.
Note: This discussion summary was generated from an AI condensation of post data.
Pasithea Therapeutics Insider Trading Activity
Pasithea Therapeutics insiders have traded $KTTA stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $KTTA stock by insiders over the last 6 months:
- LAWRENCE STEINMAN purchased 133,333 shares for an estimated $99,999
- TIAGO MARQUES (Chief Executive Officer) purchased 33,333 shares for an estimated $24,999
- SIMON DUMESNIL purchased 33,333 shares for an estimated $24,999
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Pasithea Therapeutics Hedge Fund Activity
We have seen 12 institutional investors add shares of Pasithea Therapeutics stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADVISORSHARES INVESTMENTS LLC added 64,149 shares (+33.1%) to their portfolio in Q3 2025, for an estimated $46,944
- VANGUARD GROUP INC added 53,815 shares (+inf%) to their portfolio in Q3 2025, for an estimated $39,381
- TWO SIGMA INVESTMENTS, LP added 35,760 shares (+inf%) to their portfolio in Q3 2025, for an estimated $26,169
- XTX TOPCO LTD added 34,358 shares (+inf%) to their portfolio in Q3 2025, for an estimated $25,143
- RENAISSANCE TECHNOLOGIES LLC added 30,700 shares (+inf%) to their portfolio in Q3 2025, for an estimated $22,466
- GEODE CAPITAL MANAGEMENT, LLC added 25,475 shares (+inf%) to their portfolio in Q3 2025, for an estimated $18,642
- VIRTU FINANCIAL LLC added 25,075 shares (+inf%) to their portfolio in Q3 2025, for an estimated $18,349
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
